Orthopaedic, Aichi Cancer Center, Nagoya, Aichi, Japan
Orthopaedic, Aichi Cancer Center, Nagoya, Aichi, Japan.
BMJ Case Rep. 2021 Nov 11;14(11):e245022. doi: 10.1136/bcr-2021-245022.
In recent years, denosumab has been used to treat giant cell tumour of bone (GCTB) not only in cases where surgery is complicated but also preoperatively to decrease the preoperative grade or to facilitate surgery for Campanacci grade II and III cases. However, there are no clear protocols regarding the preoperative use of denosumab before en bloc resection. There are a few reports of recurrent cases after en bloc resection; however, the association with the use of denosumab is unknown. We present the clinical, radiological and histopathological findings of a case of Campanacci grade III GCTB at the distal end of the ulna, which resulted in soft tissue recurrence after en bloc resection with the preoperative use of denosumab.
近年来,地舒单抗不仅用于治疗手术复杂的骨巨细胞瘤(GCTB),也用于术前降低术前分级或为 Campanacci 分级 II 级和 III 级病例的手术提供便利。然而,在整块切除术前使用地舒单抗还没有明确的方案。有少数关于整块切除术后复发的报道;然而,与地舒单抗的使用的关系尚不清楚。我们报告了一例尺骨远端 Campanacci 分级 III 级 GCTB 的临床、影像学和组织病理学发现,在术前使用地舒单抗进行整块切除后出现软组织复发。